1
|
Peichl P, Bayes-Genis A, Deneke T, Chioncel O, deRiva M, Crespo-Leiro MG, Frontera A, Gustafsson F, Martins RP, Pagnesi M, Maury P, Petrie MC, Sacher F, Amir O. Drug therapy and catheter ablation for management of arrhythmias in continuous flow left ventricular assist device's patients: a Clinical Consensus Statement of the European Heart Rhythm Association and the Heart Failure Association of the ESC. Europace 2024; 26:euae272. [PMID: 39478667 PMCID: PMC11580222 DOI: 10.1093/europace/euae272] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2024] [Accepted: 10/17/2024] [Indexed: 11/22/2024] Open
Abstract
Left ventricular assist devices (LVADs) are an increasingly used strategy for the management of patients with advanced heart failure. Although these devices effectively improve survival, atrial and ventricular arrhythmias are common with a prevalence of 20-50% at one year after LVAD implantation. Arrhythmias predispose these patients to additional risk and are associated with considerable morbidity from recurrent implantable cardioverter-defibrillator shocks, progressive failure of the unsupported right ventricle, and herald an increased risk of mortality. Management of patients with arrhythmias and LVAD differs in many aspects from the general population heart failure patients. These include ruling out the reversible causes of arrhythmias that in LVAD patients may include mechanical irritation from the inflow cannula and suction events. For patients with symptomatic arrhythmias refractory to medical treatment, catheter ablation might be relevant. There are specific technical and procedural challenges perceived to be unique to LVAD-related ventricular tachycardia (VT) ablation such as vascular and LV access, signal filtering, catheter manoeuvrability within decompressed chambers, and electroanatomic mapping system interference. In some patients, the arrhythmogenic substrate might not be readily accessible by catheter ablation after LVAD implantation. In this regard, the peri-implantation period offers a unique opportunity to surgically address arrhythmogenic substrate and suppress future VT recurrences. This document aims to address specific aspects of the management of arrhythmias in LVAD patients focusing on anti-arrhythmic drug therapy and ablations.
Collapse
Affiliation(s)
- Petr Peichl
- Department of Cardiology, IKEM, Vídeňská 1958/9, Prague, Czech Republic
| | - Antoni Bayes-Genis
- Heart Institute at Hospital Universitari Germans Trias i Pujol, CIBERCV, Badalona, Spain
| | - Thomas Deneke
- Clinic for Arrhythmology, Klinikum Nuernberg Süd, University Hospital of the Paracelsus Medical University, Nuernberg, Germany
| | - Ovidiu Chioncel
- Institute of Emergency for Cardiovascular Diseases, ‘C.C.Iliescu’ Bucharest, Romania
- University of Medicine Carol Davila, Bucharest, Romania
| | - Marta deRiva
- Leiden University Medical Center, Leiden, The Netherlands
| | - Maria Generosa Crespo-Leiro
- Complexo Hospitalario Universitario A Coruña (CHUAC)-CIBERCV, Instituto de Investigación Biomedica A Coruña (INIBIC), Universidad de A Coruña (UDC), A Coruña, Spain
| | - Antonio Frontera
- Department of Cardiac Electrophysiology, Great Metropolitan Hospital Niguarda, Milan, Italy
| | | | - Raphaël P Martins
- Department of Cardiology, University Hospital of Rennes, Rennes, France
| | - Matteo Pagnesi
- Department of Medical and Surgical Specialties, Radiological sciences and Public Health, Institute of Cardiology, ASST Spedali Civili, University of Brescia, Brescia, Italy
| | - Philippe Maury
- Department of Cardiology, Rangueil Hospital of Toulouse, Toulouse, France
| | - Mark C Petrie
- School of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK
| | - Frederic Sacher
- Cardiac Arrhythmia Department, Univ. Bordeaux, CHU de Bordeaux, INSERM, CRCTB, U 1045, IHU Liryc, Bordeaux, France
| | - Offer Amir
- Heart Center, Hadassah Medical Center and Hebrew University, Jerusalem, Israel
| |
Collapse
|
2
|
[Cardiac rehabilitation in LVAD patients : Aspects regarding exercise and rhythm]. Herzschrittmacherther Elektrophysiol 2023; 34:45-51. [PMID: 36580090 DOI: 10.1007/s00399-022-00914-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2022] [Accepted: 12/05/2022] [Indexed: 12/30/2022]
Abstract
After implantation of a left ventricular assist device (LVAD), it is strongly recommended that patients participate in an inpatient cardiac rehabilitation program (CR). Relevant topics during CR include sports and exercise therapy as well as aspects of cardiac rhythm control. Over time, LVAD patients usually regain a good quality of life and an adequate functional capacity can be observed. However, maximum performance values remain markedly reduced, in part due to the fixed LVAD pump speed and the limited total cardiac output. Therefore, structured long-term exercise training programs (even beyond CR phase II) are of particular importance in order to optimize neuromuscular control and muscle metabolism. Limitations to physical performance values may also be caused by the occurrence of supraventricular and/or ventricular arrhythmias. In both cases, the cause is an increasing hemodynamic impairment of the right heart, which may also lead to a reduced LVAD pump flow. In addition, inadequate setting of other cardiac implantable electronic devices (e.g., implantable cardioverter-defibrillator [ICD] or cardiac resynchronization therapy with defibrillator [CRT-D]) may also have a crucial impact on hemodynamics after LVAD implantation. In this article, we will discuss specific aspects of LVAD therapy related to exercise and rhythm control, particularly in the context of CR programs.
Collapse
|